Drugs like Humira® (adalimumab) may help relieve Crohn’s disease, ulcerative colitis, and other chronic conditions, but they can easily cost thousands of dollars out of pocket. Less-expensive versions of these drugs, known as biosimilars, could be an option for many IBD patien...

In July, the U.S. Food & Drug Administration (FDA) made two announcements regarding IBD treatments: New HUMIRA® biosimilar approved for ulcerative colitis and adult Crohn’s disease patients The FDA announced the approval of HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMI...